Parareg

RSS

Withdrawn

This medicine's authorisation has been withdrawn

cinacalcet
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 22 October 2004 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Parareg, cinacalcet. Parareg is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, and for the reduction of hypercalcaemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels but in whom parathyroidectomy is not clinically appropriate or is contraindicated. 

The marketing authorisation holder (MAH) responsible for Parareg was Dompé Biotec S.p.A. The European Commission was notified by letter dated 10 November 2008 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Parareg for commercial reasons. 

Parareg was only marketed in Italy. Mimpara is an identical product available in the European Union. Patients have therefore been switched to Mimpara. On 5 December 2008 the European Commission issued a decision to withdraw the marketing authorisation for Parareg. 

Pursuant to this decision the European Public Assessment Report for Parareg is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (407.85 kB - PDF)

Bekijk

español (ES) (270.36 kB - PDF)

Bekijk

čeština (CS) (391.51 kB - PDF)

Bekijk

dansk (DA) (269.6 kB - PDF)

Bekijk

Deutsch (DE) (271.46 kB - PDF)

Bekijk

eesti (ET) (307.8 kB - PDF)

Bekijk

ελληνικά (EL) (404.21 kB - PDF)

Bekijk

français (FR) (271.07 kB - PDF)

Bekijk

italiano (IT) (270.63 kB - PDF)

Bekijk

latviešu (LV) (389.42 kB - PDF)

Bekijk

lietuvių (LT) (387.52 kB - PDF)

Bekijk

magyar (HU) (380.13 kB - PDF)

Bekijk

Malti (MT) (391.48 kB - PDF)

Bekijk

Nederlands (NL) (270.52 kB - PDF)

Bekijk

polski (PL) (398.6 kB - PDF)

Bekijk

português (PT) (270.61 kB - PDF)

Bekijk

română (RO) (380.1 kB - PDF)

Bekijk

slovenčina (SK) (385.62 kB - PDF)

Bekijk

slovenščina (SL) (376.47 kB - PDF)

Bekijk

suomi (FI) (270.06 kB - PDF)

Bekijk

svenska (SV) (269.32 kB - PDF)

Bekijk

Product information

български (BG) (1.2 MB - PDF)

Bekijk

español (ES) (901.88 kB - PDF)

Bekijk

čeština (CS) (1.05 MB - PDF)

Bekijk

dansk (DA) (825.74 kB - PDF)

Bekijk

Deutsch (DE) (869.84 kB - PDF)

Bekijk

eesti (ET) (944.64 kB - PDF)

Bekijk

ελληνικά (EL) (1.32 MB - PDF)

Bekijk

français (FR) (920.91 kB - PDF)

Bekijk

italiano (IT) (847.73 kB - PDF)

Bekijk

latviešu (LV) (1.1 MB - PDF)

Bekijk

lietuvių (LT) (1.02 MB - PDF)

Bekijk

magyar (HU) (984.21 kB - PDF)

Bekijk

Malti (MT) (995.38 kB - PDF)

Bekijk

Nederlands (NL) (797.04 kB - PDF)

Bekijk

polski (PL) (1.1 MB - PDF)

Bekijk

português (PT) (270.61 kB - PDF)

Bekijk

română (RO) (380.1 kB - PDF)

Bekijk

slovenčina (SK) (385.62 kB - PDF)

Bekijk

slovenščina (SL) (376.47 kB - PDF)

Bekijk

suomi (FI) (815.99 kB - PDF)

Bekijk

svenska (SV) (269.32 kB - PDF)

Bekijk
Latest procedure affecting product information:II/0015
29/10/2008
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

español (ES) (278.46 kB - PDF)

Bekijk

čeština (CS) (301.78 kB - PDF)

Bekijk

dansk (DA) (280.2 kB - PDF)

Bekijk

Deutsch (DE) (281.12 kB - PDF)

Bekijk

eesti (ET) (279.83 kB - PDF)

Bekijk

ελληνικά (EL) (298.99 kB - PDF)

Bekijk

français (FR) (279.51 kB - PDF)

Bekijk

italiano (IT) (278.06 kB - PDF)

Bekijk

latviešu (LV) (298.54 kB - PDF)

Bekijk

lietuvių (LT) (299.23 kB - PDF)

Bekijk

magyar (HU) (299.73 kB - PDF)

Bekijk

Nederlands (NL) (279.14 kB - PDF)

Bekijk

polski (PL) (303.49 kB - PDF)

Bekijk

português (PT) (277.01 kB - PDF)

Bekijk

slovenčina (SK) (301.84 kB - PDF)

Bekijk

slovenščina (SL) (299.12 kB - PDF)

Bekijk

suomi (FI) (278.28 kB - PDF)

Bekijk

svenska (SV) (278.89 kB - PDF)

Bekijk

Product details

Name of medicine
Parareg
Active substance
cinacalcet
International non-proprietary name (INN) or common name
cinacalcet
Therapeutic area (MeSH)
  • Hypercalcemia
  • Parathyroid Neoplasms
  • Hyperparathyroidism
Anatomical therapeutic chemical (ATC) code
H05BX01

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).

Reduction of hypercalcaemia in patients with:

  • parathyroid carcinoma.
  • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium
    levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Authorisation details

EMA product number
EMEA/H/C/000575
Marketing authorisation holder
Dompé Biotec S.p.A.

Via San Martino 12
I-20122 Milan
Italy

Marketing authorisation issued
22/10/2004
Withdrawal of marketing authorisation
05/12/2008
Revision
6

Assessment history

This page was last updated on

Share this page